Using eClinical Systems for Supply-Chain Management

Published on: 

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-05-07-2014, Volume 10, Issue 5

Kurt Lumsden, Director, eCDS Client Services at PAREXEL Informatics, discusses eClinical supply-chain management.

Q. How can eClinical systems support end-to-end supply-chain management?

Advertisement

A. Maintaining clinical supply chain integrity is crucial to trial success. The supply chain can encounter many challenges, including more countries and more investigator sites supplied by yet more depots, thus increasing demands on the entire supply chain. Other issues may include inventory dispersion throughout the supply chain, expiry issues, myriad storage and temperature management requirements, and the implications of more complex study designs.

eClinical systems support effective, efficient, and flexible clinical supply-chain management to help mitigate these challenges at every stage of the product lifecycle, from release through final destruction. eClinical supply chain management (eCSCM) applications used in such systems typically include interactive response technologies (IRT) and web-based applications, such as distribution management systems and drug accountability applications, as well as mobile apps. The purpose of an eCSCM system is to add value through increased agility (i.e., build and post-build agility), improved usability, and enhanced flexibility, while reducing costs, mitigating risk, and ensuring compliance with all applicable regulations (1). Common features of effective eCSCM solutions include:

  • Agility—Allowing for rapid system deployment and change management

  • Scalability—A platform that can support simple and complex trial designs

  • Usability—Streamlined user interface with single sign-on and data aggregation

  • Flexibility—Accommodate basic as well as complex functionality requirements

  • Control—Effective tools for study, product, site, and subject management

  • Visibility—Insight into investigational product (IP) at each trial level (e.g., study, country, depot, site, subject, visit, pack)

  • Traceability—Current and historic information on IP/Investigational Medicinal Product (IMP) pack and component status, location, and disposition

  • Compliance monitoring—Through system error checks, reporting, alerts, and reminders to users/stakeholders to ensure on-time completion of user activities and supply-chain management (SCM) tasks.

Clinical-trial sponsors need to ensure availability of the IP (in addition to comparators, ancillaries, and medical devices) required for study sites to successfully enroll study subjects in support of on-time trial completion. This is also crucial for navigating the various regulations and guidelines that maintain trial participant safety.
In clinical trials, eCSCM systems must be able to:

  • Prevent allocation of IP that will expire before use

  • Manage and replace unusable product

  • Support pooled supplies

  • Support direct-to-patient ordering

  • Maintain the study blind

  • Prevent depot/site stock-outs

  • Reduce the need for partial allocations

  • Update expiry dating throughout the chain of distribution

  • Minimize IP wastage, shipping frequency, and costs

  • Mitigate unplanned repackaging of additional supplies

  • Conform to site storage constraints

  • Integrate with other eClinical systems

  • Provide visibility of IP status, usability expiry, and disposition.

Additional requirements can include: Accommodation of eLabel requirements (2); implementation of needs-based product ordering; management of shipping and allocation expiry offsets, support of consecutive, concurrent, and alternate product allocations; and flexible reporting and forecasting  solutions (including the ability to conduct pre-study and mid-study supply chain simulations) by study, depot, country, or site.

Supply-chain management
eCSCM systems typically support the following supply-chain management functions:

  • Lot release for both uniquely and non-uniquely numbered supplies

  • QP management, including the ability for lots to be re-released if expiry is updated

  • Expiry management in tandem with study, country, or location updates

  • Site management, setting recruitment status, and supply schemes

  • Site inventory management--managing product by consignments or individual item

  • Supply strategy management (the ability to adjust floor and ceiling supply strategy levels as trial enrollment progresses)

  • Status management (managing product status including cold chain management)

  • Shipment ordering, receipt, dispatch, and proof of delivery

  • IP allocation and dosing

  • IP returns, accountability, reconciliation, and destruction.

New approaches are also being used to better manage site and subject compliance with the goal of reducing storage and dosing errors. Strategies can include delivery of product storage, allocation/administration instructions, and compliance assessments, all delivered through various modalities such as IRT, short message service (SMS), or mobile app. These systems work together within a network:

  • Basic eClinical supply chain management networks do not integrate activities such as manufacturing, storage, release, distribution, allocation, returns, and destruction.

  • Enhanced eClinical supply chain management networks utilize integrated eClinical systems to manage supply-chain activities such as release, ordering, allocation, returns, and destruction.

  • Optimized eClinical supply chain management networks provide further overall synergy through deeper integration and harmonization.

Benefits of eCSCM
Maximizing the use of this technology confers the following benefits:  Process efficiencies and automation drive decreased cycle times; accelerated decision-making through improved data visibility; reduction of data duplication; and additional effort as well as better enforcement of data quality.

Using the right eClinical supply chain management systems and network to manage the trial supply chain can greatly simplify the journey for sponsors, allowing for on-time completion of trials with reduced risk, better cost control, and an improved stakeholder experience.  

References
1. ICH, Q9 Quality Risk Management, p20 (ICH, 2006), www.fda.gov/cder/guidance/index.htm, accessed Mar. 7, 2014.
2. FDA, Guidance for Industry, Standards for Securing the Drug Supply Chain—Standardized Numerical Identification for Prescription Drug Packages. Final Guidance (2010), www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, accessed Mar. 7, 2014.

About the Author
Kurt Lumsden is director, eCDS Client Services at PAREXEL Informatics.